Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
Your search for bevacizumab returned 5 results
There was no improvement in overall survival with bevacizumab.
The approval was based on data from the phase 3 KEYNOTE-826 trial.
The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.
Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.